| Followers | 42 |
| Posts | 4316 |
| Boards Moderated | 0 |
| Alias Born | 07/14/2010 |
Monday, October 02, 2023 12:27:39 PM
Profitability
Profit Margin 0.00%
Operating Margin 0.00%
$300,000,000 entering the market
24,000,000 shares @ $12.49 being sold
Profit Margin 0.00%
Operating Margin 0.00%
$300,000,000 entering the market
24,000,000 shares @ $12.49 being sold
Recent GPCR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:45:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:42:51 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2026 08:17:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:35:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:30:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 10:05:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:01:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:20:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:20:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:20:09 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/26/2026 10:22:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:11:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 09:07:35 PM
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity • GlobeNewswire Inc. • 12/17/2025 01:30:00 PM
- Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs • GlobeNewswire Inc. • 12/11/2025 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 10:06:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/10/2025 10:04:01 PM
- Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants • GlobeNewswire Inc. • 12/10/2025 04:15:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/08/2025 10:28:16 PM
- Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants • GlobeNewswire Inc. • 12/08/2025 09:01:00 PM
- Structure Therapeutics surges as oral GLP-1 candidate delivers standout weight-loss results • IH Market News • 12/08/2025 03:22:16 PM
